Journey of a DDR Patient Sample: De-risking Preclinical and Clinical Research
Time: 12:30 pm
day: Day One Track B AM
Details:
- Advanced CTC isolation with Parsortix® FDA-510k cleared capture technology
- Integration of CTCs with known DDR biomarker assays
- Provide strategies to minimize risks in the development of targeted DDR therapies
- Explore future approaches to evaluate DDR inhibitors based upon responses guided by Parsortix enriched CTCs
